dalfampridine

ROUTE	ONSET	PEAK	DURATION
PO	unknown	3–4 hr	24 hr

Contraindicated in:

Hypersensitivity;
History of seizures;
Moderate/severe renal impairment (CCr ≤50 mL/min)(↑ risk of seizures).

Use Cautiously in:

Mild renal impairment (CCr 51–80 mL/min) (↑ risk of seizures);
OB: Safety not established in pregnancy;
Lactation: Safety not established in breastfeeding;
Pedi: Safety and effectiveness not established in children;
Geri: Consider age-related in renal function in older adults.

Adv. Reactions/Side Effects ⬆ ⬇

EENT: nasopharyngitis, pharyngolaryngeal pain

GI: constipation, dyspepsia, nausea

GU: urinary tract infection

MS: back pain

Neuro: dizziness, headache, insomnia, multiple sclerosis relapse, paresthesia, SEIZURES, vertigo, weakness

Misc: ANAPHYLAXIS

Interactions ⬆ ⬇

Drug-drug:

Cimetidine may ↑ levels and ↑ risk of seizures.

Route/Dosage ⬆ ⬇

PO (Adults ): 10 mg twice daily.

Availability ⬆ ⬇

(Generic available)

Extended-release tablets: 10 mg

Assessment ⬆ ⬇

Assess walking speed in patients with multiple sclerosis prior to and periodically during therapy.
Monitor for seizures during therapy, risk increases with increased dose. If seizure occurs, discontinue therapy.
Monitor for signs and symptoms of anaphylaxis (dyspnea, wheezing, urticaria, angioedema of the throat or tongue) during therapy.

Lab Test Considerations:

Monitor CCr prior to and at least yearly during therapy; renal impairment may require dose reduction or discontinuation.

Implementation ⬆ ⬇

Administer tablets twice daily approximately 12 hr apart without regard to food. DNC: Swallow tablets whole; do not break, crush, chew, or dissolve.

Patient/Family Teaching ⬆ ⬇

Instruct patient to take dalfampridine as directed, with approximately 12 hr between tablets. If a dose is missed, omit and take next scheduled dose on time; do not double doses. May increase risk of seizures. Advise patient to read Medication Guide prior to beginning therapy and with each Rx refill in case of changes.
May cause vertigo, dizziness, and seizures. Caution patient to avoid driving and other activities requiring alertness until response to the drug is known.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
If a seizure or signs or symptoms of anaphylaxis occur, advise patient to notify health care professional immediately, to discontinue dalfampridine, and to not restart medication.
Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes ⬆ ⬇

Improved walking and increased walking speed in patients with multiple sclerosis.

US Brand Names ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Code ⬆

NDC Code

0378- Mylan Pharmaceuticals Inc.
- 0378-0509- dalfampridine
  - 0378-0509-91- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-0509-91)

10144- Acorda Therapeutics, Inc.
- 10144-427- AMPYRA
  - 10144-427-60- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (10144-427-60)

16729- Accord Healthcare Inc.
- 16729-292- Dalfampridine
  - 16729-292-12- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (16729-292-12)

42571- Micro Labs Limited
- 42571-275- DALFAMPRIDINE
  - 42571-275-05- 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (42571-275-05)

42571- Micro Labs Limited
- 42571-275- DALFAMPRIDINE
  - 42571-275-10- 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (42571-275-10)

42571- Micro Labs Limited
- 42571-275- DALFAMPRIDINE
  - 42571-275-60- 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (42571-275-60)

62756- Sun Pharmaceutical Industries, Inc.
- 62756-429- Dalfampridine
  - 62756-429-86- 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (62756-429-86)

65862- Aurobindo Pharma Limited
- 65862-863- DALFAMPRIDINE
  - 65862-863-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-863-01)

65862- Aurobindo Pharma Limited
- 65862-863- DALFAMPRIDINE
  - 65862-863-05- 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-863-05)

65862- Aurobindo Pharma Limited
- 65862-863- DALFAMPRIDINE
  - 65862-863-60- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-863-60)

67877- Ascend Laboratories, LLC
- 67877-444- Dalfampridine
  - 67877-444-05- 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (67877-444-05)

67877- Ascend Laboratories, LLC
- 67877-444- Dalfampridine
  - 67877-444-60- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (67877-444-60)

67877- Ascend Laboratories, LLC
- 67877-444- Dalfampridine
  - 67877-444-90- 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (67877-444-90)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇